Expertise in
12
conditions

Dr. Martin R. Farlow

Neurology
Indiana University Medical Center
545 Barnhill Dr, 
Indianapolis, IN 
Accepting New Patients
Offers Telehealth
Expertise in
12
conditions
Indiana University Medical Center
545 Barnhill Dr, 
Indianapolis, IN 

Overview

Martin Farlow is a Neurologist practicing medicine in Indianapolis, Indiana.

Dr. Farlow is highly rated in 12 conditions, according to our data. His clinical expertise encompasses Alzheimer's Disease, Dementia, Gerstmann-Straussler-Scheinker Syndrome, and Frontotemporal Dementia.

He is actively involved in clinical research, co-authoring 204 peer reviewed articles and participating in 10 clinical trials. Dr. Farlow is currently accepting new patients.

Specialties

Neurology

Licenses

Psychiatry & Neurology in IN

Hospital Affiliations

Indiana University Health Bloomington Hospital
Indiana University Health
Indiana University Health North Hospital

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
CareSource
  • HMO
Cigna
  • EPO
  • HMO
  • PPO
Health Alliance
  • EPO
  • HMO
  • POS
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Highmark
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
MDwise
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • OTHER COMMERCIAL
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Medicare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE PART D
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Zing Health
  • MEDICARE MAPD
  • MEDICARE SNP
View 11 Less Insurance Carriers -

Locations

Indiana University Medical Center
545 Barnhill Dr, Indianapolis, IN 46202

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

10 Clinical Trials

Anti-Amyloid Treatment in Asymptomatic Alzheimer's Disease (A4 Study)
Anti-Amyloid Treatment in Asymptomatic Alzheimer's Disease (A4 Study)
Enrollment Status: Completed
Publish Date: August 21, 2026
Intervention Type: Drug
Study Drug: Solanezumab
Study Phase: Phase 3
Alzheimer's Disease Neuroimaging Initiative 3 (ADNI3)
Alzheimer's Disease Neuroimaging Initiative 3 (ADNI3)
Enrollment Status: Completed
Publish Date: March 11, 2026
SEMA4D Blockade Safety and Brain Metabolic Activity in Alzheimer's Disease (AD): A Multi-center, Randomized, Double-Blind, Placebo-Controlled Safety and Biomarker Study of Pepinemab Anti-SEMA4D Antibody in Early-AD
SEMA4D Blockade Safety and Brain Metabolic Activity in Alzheimer's Disease (AD): A Multi-center, Randomized, Double-Blind, Placebo-Controlled Safety and Biomarker Study of Pepinemab Anti-SEMA4D Antibody in Early-AD
Enrollment Status: Completed
Publish Date: August 22, 2024
Intervention Type: Drug
Study Drug: Pepinemab
Study Phase: Phase 1/Phase 2
Trial Ready Cohort for the Prevention of Alzheimer's Dementia (TRC-PAD)
Trial Ready Cohort for the Prevention of Alzheimer's Dementia (TRC-PAD)
Enrollment Status: Completed
Publish Date: June 27, 2024
Multiple-Dose, Dose-Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of LY3303560 in Patients With Mild Cognitive Impairment Due to Alzheimer's Disease or Mild to Moderate Alzheimer's Disease
Multiple-Dose, Dose-Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of LY3303560 in Patients With Mild Cognitive Impairment Due to Alzheimer's Disease or Mild to Moderate Alzheimer's Disease
Enrollment Status: Completed
Publish Date: October 10, 2023
Intervention Type: Drug
Study Phase: Phase 1
A Phase 2a Multicenter, Randomized, Double-Blind, Parallel Group, 26-Week, Placebo-Controlled Study of SUVN-502 in Subjects With Moderate Alzheimer's Disease Currently Treated With Donepezil Hydrochloride and Memantine Hydrochloride
A Phase 2a Multicenter, Randomized, Double-Blind, Parallel Group, 26-Week, Placebo-Controlled Study of SUVN-502 in Subjects With Moderate Alzheimer's Disease Currently Treated With Donepezil Hydrochloride and Memantine Hydrochloride
Enrollment Status: Completed
Publish Date: June 09, 2023
Intervention Type: Drug
Study Phase: Phase 2
A Phase 3 Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Aducanumab (BIIB037) in Subjects With Early Alzheimer's Disease
A Phase 3 Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Aducanumab (BIIB037) in Subjects With Early Alzheimer's Disease
Enrollment Status: Terminated
Publish Date: September 02, 2021
Intervention Type: Drug
Study Phase: Phase 3
Effect of LY3202626 on Alzheimer's Disease Progression as Measured by Cerebral ¹⁸F-AV-1451 Tau-PET in Mild Alzheimer's Disease Dementia
Effect of LY3202626 on Alzheimer's Disease Progression as Measured by Cerebral ¹⁸F-AV-1451 Tau-PET in Mild Alzheimer's Disease Dementia
Enrollment Status: Terminated
Publish Date: April 19, 2021
Intervention Type: Drug
Study Phase: Phase 2
A 24-month, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Efficacy, Safety, Tolerability, Biomarker, and Pharmacokinetic Study of AZD3293 in Early Alzheimer's Disease (The AMARANTH Study)
A 24-month, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Efficacy, Safety, Tolerability, Biomarker, and Pharmacokinetic Study of AZD3293 in Early Alzheimer's Disease (The AMARANTH Study)
Enrollment Status: Terminated
Publish Date: December 03, 2019
Intervention Type: Drug
Study Phase: Phase 2/Phase 3
A 24-Month, Phase 3, Multicenter, Placebo-Controlled Study of Efficacy and Safety of Solanezumab Versus Placebo in Prodromal Alzheimer's Disease
A 24-Month, Phase 3, Multicenter, Placebo-Controlled Study of Efficacy and Safety of Solanezumab Versus Placebo in Prodromal Alzheimer's Disease
Enrollment Status: Terminated
Publish Date: October 10, 2019
Intervention Type: Drug
Study Phase: Phase 3
View 9 Less Clinical Trials

201 Total Publications

Effect of Cognitive Reserve on Age at Symptom Onset and Cognitive Decline in Individuals With Dominantly Inherited Alzheimer Disease.
Effect of Cognitive Reserve on Age at Symptom Onset and Cognitive Decline in Individuals With Dominantly Inherited Alzheimer Disease.
Journal: Neurology
Published: April 08, 2026
Similar Doctors
Expertise in
44
conditions
Expertise in
44
conditions
Referral may be required

Indiana University Psychiatric Associates Inc.

355 W 16th St, 
Indianapolis, IN 
 (1.1 miles away)
317-963-7000
Experience:
47+ years
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Robert Pascuzzi is a Neurologist practicing medicine in Indianapolis, Indiana. He has been practicing medicine for over 47 years. Dr. Pascuzzi is highly rated in 44 conditions, according to our data. His clinical expertise encompasses Myasthenia Gravis, Lambert-Eaton Syndrome, Amyotrophic Lateral Sclerosis (ALS or Lou Gehrig's Disease), Spinal and Bulbar Muscular Atrophy, and Thymectomy. Dr. Pascuzzi is currently accepting new patients.

Expertise in
12
conditions
Expertise in
12
conditions
Referral may be required

Office

250 N Shadeland Ave, 
Indianapolis, IN 
 (6.9 miles away)
317-948-5450
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Liana Apostolova is a Neurologist practicing medicine in Indianapolis, Indiana. Dr. Apostolova is highly rated in 12 conditions, according to our data. Her clinical expertise encompasses Alzheimer's Disease, Dementia, Primary Amyloidosis, and Developmental Dysphasia Familial. Dr. Apostolova is currently accepting new patients.

Expertise in
79
conditions
Expertise in
79
conditions
Referral required
Before you request

Indiana University Health University Hospital

550 University Blvd, 
Indianapolis,, IN 
 (0.1 miles away)
317-274-8800
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Cynthia Bodkin is a Neurologist practicing medicine in Indianapolis,, Indiana. Dr. Bodkin is highly rated in 79 conditions, according to our data. Her clinical expertise encompasses Amyotrophic Lateral Sclerosis (ALS or Lou Gehrig's Disease), Spinal Muscular Atrophy (SMA), Spinal Muscular Atrophy Type 3, and Spinal and Bulbar Muscular Atrophy. Dr. Bodkin is currently accepting new patients.

Frequently Asked Questions about Dr. Martin R. Farlow

How do I make an appointment with Dr. Martin R. Farlow?

You can book an appointment with Dr. Martin R. Farlow by calling their office at 317-274-8800. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Martin R. Farlow a top-rated expert for Alzheimer's Disease?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Martin R. Farlow is classified as an Elite expert for Alzheimer's Disease, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Martin R. Farlow specialize in?

While Dr. Martin R. Farlow is a Neurology, they have specific expertise in Alzheimer's Disease, Dementia, and Gerstmann-Straussler-Scheinker Syndrome. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Neurology.

Does Dr. Martin R. Farlow participate in research or clinical trials?

Yes. Dr. Martin R. Farlow has published 201 articles and abstracts on conditions like Alzheimer's Disease. You can view a list of Dr. Martin R. Farlow's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Martin R. Farlow accept my insurance?

Dr. Martin R. Farlow accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 317-274-8800 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Farlow's expertise for a condition
ConditionClose
View All 7 Advanced Conditions
View All 29 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile